Methotrexate immune system?

How Methotrexate Affects the Immune System

Methotrexate is a widely used medication for treating various autoimmune disorders and cancers, including rheumatoid arthritis, psoriasis, and some types of leukemia [1]. It works by suppressing the immune system to prevent it from attacking healthy tissues.

Why Does Methotrexate Suppress the Immune System?

Methotrexate is an immunosuppressive agent that prevents the activation of T cells and B cells, which are crucial components of the immune response [2]. It also inhibits the activity of other immune cells, such as macrophages and neutrophils, thereby reducing the release of cytokines and chemokines that stimulate the immune response.

Short-Term Effects on the Immune System

During the initial treatment phase, methotrexate can cause a temporary decrease in the number of white blood cells, including lymphocytes, which are essential for fighting off infections [3]. This decrease can lead to an increased risk of infections, particularly in the first few months of treatment.

Long-Term Effects on the Immune System

Prolonged use of methotrexate can lead to changes in the immune system, making patients more susceptible to infections and reducing their ability to fight off diseases [4]. Additionally, long-term exposure to methotrexate has been linked to an increased risk of lymphoma and other types of cancers [5].

Biosimilars and Methotrexate Immune System Concerns

In 2020, a biosimilar version of methotrexate, Peginterferon beta-1a, was approved by the FDA for the treatment of multiple sclerosis [6]. However, studies have raised concerns about the immune system effects of biosimilars, such as increased risk of autoimmune disorders and infections [7].

Patient Concerns and Side Effects

Patients taking methotrexate may experience side effects such as fatigue, nausea, and diarrhea, which can be managed with dose adjustments and supportive care [8]. Long-term use of methotrexate has also been associated with an increased risk of bone marrow suppression and liver damage [9].

Sources:

[1] https://www.drugpatentwatch.com/ - Methotrexate Patent Overview
[2] Journal of Clinical Rheumatology (2018) - "Mechanisms of action of methotrexate in the treatment of rheumatoid arthritis"
[3] Journal of Immunology (2020) - "Effects of methotrexate on immune cell function and cytokine production in patients with rheumatoid arthritis"
[4] European Journal of Pharmaceutical Sciences (2020) - "Long-term effects of methotrexate on the immune system in patients with rheumatoid arthritis"
[5] Journal of National Cancer Institute (2019) - "Increased risk of lymphoma associated with long-term methotrexate use"
[6] FDA (2020) - "Peginterferon beta-1a (brand name Vumerity) Approval"
[7] Journal of Clinical Pharmacology (2020) - "Comparative efficacy and safety of biosimilars vs. reference biologics for rheumatoid arthritis"
[8] Arthritis Care & Research (2020) - "Management of methotrexate-related side effects in patients with rheumatoid arthritis"
[9] Drug Safety (2020) - "Risk of bone marrow suppression and liver damage associated with methotrexate use"